A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if intermittent (occasional) chemotherapy added to immunotherapy will work better than immunotherapy alone. Participation in this research will last about two years.

Trial Details

NCT ID
NCT05420948
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Pembrolizumab
  • Carboplatin
  • Paclitaxel
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Have clinically confirmed head and neck cancer that is recurrent (comes back/returns to the body) or metastatic (spreads to other parts of the body).
  • Participants should not have had prior systemic therapy administered in the recurrent or metastatic setting. Systemic therapy which was completed m…
  • Greater than or equal to 18 years old.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →